Improving Colorectal Cancer Screening Rates and Quality
Registration |
---|
Two attendance options:
|
Target Audience
DMU faculty, staff, students, residents, and the medical community.
Educational Need
The State Health Registry reports that colorectal cancer is the second leading cause of cancer death in Iowa men and women combined. An estimated 590 Iowans will die from the disease in 2016. Yet, colorectal cancer is highly preventable and highly treatable when found in the earliest stages.
Objectives
- Understand common barriers to colorectal cancer screening and strategies to overcome them.
- Discuss key practice-change elements to increase screening rates.
- Identify elements of high quality testing programs.
Durado Brooks, MD, MPH
Managing Director, Cancer Control Intervention, American Cancer Society
Dr. Brooks has worked for the American Cancer Society’s national headquarters since 2000. He is involved in the creation and implementation of strategies to improve the prevention and early detection of cancer and to reduce cancer disparities. He also serves as Deputy Editor of the Society’s peer-reviewed journal CA: A Cancer Journal for Clinicians.
A graduate of the Ohio State University and the Wright State University School of Medicine, Dr. Brooks completed his internal medicine residency and chief residency at Wright State’s Affiliated Hospitals in Dayton, Ohio. He completed the Commonwealth Fund/Harvard University Fellowship in Minority Health Policy in 1999 and holds a Master’s degree from the Harvard School of Public Health. Before joining the American Cancer Society Dr. Brooks practiced primary care medicine and served as medical director in community health centers in Ohio and in his current hometown of Dallas, TX. In 2015 Dr. Brooks was honored with the Prevent Cancer Foundation’s Laurel Award for National Leadership in cancer prevention and early detection.
Relevant to the content of this educational activity, Dr. Brooks has no financial relationships to disclose.
Accreditation Statements
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians.
DMU designates this live activity for 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA). DMU and the AOA approve this activity for 1.0 hour of Category 2-A CME credit(s).
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.2 continuing education contact hour(s). No partial credit awarded.
- Other: This live activity is designated for 1.0 AMA PRA Category 1 Credit(s)™.
Educational Grants
No commercial interest provided financial support for this continuing education activity.
DISCLOSURE
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
Available Credit
- 1.00 AMA PRA Category 1 Credits™
- 1.00 AOA Category 2A
- 1.00 CE Contact Hour(s)
- 1.20 IBON